You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Characteristics of all included HIV-1 patients and patients carrying a wild-type virus or a virus with transmitted drug resistance mutations to NRTI, NNRTI, or PI drug class

From: Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe

Characteristics Categories Total Wild-type NRTI TDRMa NNRTI TDRMa PI TDRMa
Patients   4317 3933 218 125 107
Continent of origin, no (%) Western Europe 2404 (56) 2164 (55) 135 (62) 85 (68) 66 (62)
Eastern Europe & Central Asia 919 (21) 848 (22) 48 (22) 16 (13) 17 (16)
Sub-Saharan Africa 472 (11) 442 (11) 12 (6) 11 (9) 12 (11)
Other 354 (8) 325 (8) 16 (7) 9 (7) 8 (7)
Unknown 168 (4) 154 (4) 7 (3) 28 (2) 4 (4)
Gender, no. (%) Male 3411 (79) 3084 (78) 190 (87) 107 (86) 88 (82)
Risk group, no. (%) MSM 2084 (48) 1852 (47) 138 (63) 79 (63) 57 (53)
Hetero 1501 (35) 1402 (36) 50 (23) 28 (22) 37 (35)
Injecting drug use 355 (8) 337 (9) 7 (3) 10 (8) 5 (5)
Unknown 377 (9) 342 (9) 23 (11) 8 (6) 8 (7)
Subtype, no. (%) B 2855 (66) 2553 (65) 183 (84) 94 (75) 78 (73)
non-B 1381 (32) 1306 (33) 31 (14) 27 (22) 27 (25)
Unknown 81 (2) 74 (2) 4 (2) 4 (3) 2 (2)
Duration of infection, no (%) <1 year 1236 (29) 1099 (28) 75 (34) 49 (39) 41 (38)
1-2 years 144 (3) 130 (3) 8 (4) 6 (5) 2 (2)
Unknown 2937 (68) 2704 (69) 135 (62) 70 (56) 64 (60)
Plasma HIV-RNA, median (IQR), log copies/ml 4.9 (4.3-5.3) 4.9 (4.3-5.3) 4.9 (4.3-5.5) 4.8 (4.1-5.5) 4.7 (4.3-5.2)
CD4 cell count, median (IQR), cells/mm3 352 (180–540) 350 (177–534) 400 (186–572) 426 (275–577) 386 (251–593)
Age, median years (IQR) 35 (29–42) 35 (29–42) 35 (28–42) 35 (29–43) 34 (29–39)
  1. NOTE. NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; MSM: men who have sex with men; IQR, interquartile ranges; aTDRM’s from multiple classes was found in 49 (22.5%), 39 (31.2%), and 28 (26.2%) patients in the NRTI, NNRTI, and PI drug class, respectively, and are therefore counted in more than one drug resistance column. Multi-class resistance was found for the combination NRTI-NNRTI in 38 patients, for NRTI-PI in 27 patients and NNRTI-PI in 17 patients. Resistance for all three drug classes was found in 16 patients.